Fidelity Investments’s Juno Therapeutics, Inc. JUNO Stock Holding History

Fidelity Investments’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2,736,527	Closed	-$125M	–	2782
2017 Q4	$125M	Buy	2,736,527 +987,489	+56%	+$49.3M	0.01%	894
2017 Q3	$78.5M	Sell	1,749,038 -37,900	-2%	-$1.29M	0.01%	1086
2017 Q2	$53.4M	Sell	1,786,938 -131,654	-7%	-$3.25M	0.01%	1270
2017 Q1	$42.6M	Hold	1,918,592	–	–	0.01%	1385
2016 Q4	$36.2M	Sell	1,918,592 -1,268,166	-40%	-$31M	﹤0.01%	1441
2016 Q3	$95.6M	Sell	3,186,758 -2,520,477	-44%	-$78.4M	0.01%	999
2016 Q2	$219M	Hold	5,707,235	–	–	0.03%	627
2016 Q1	$217M	Sell	5,707,235 -1,585,989	-22%	-$55.3M	0.03%	609
2015 Q4	$321M	Buy	7,293,224 +175,800	+2%	+$8.72M	0.04%	458
2015 Q3	$290M	Buy	7,117,424 +541,134	+8%	+$23.7M	0.04%	476
2015 Q2	$351M	Buy	6,576,290 +147,659	+2%	+$7.84M	0.04%	438
2015 Q1	$390M	Buy	6,428,631 +1,193,164	+23%	+$57.9M	0.05%	417
2014 Q4	$273M	Buy	+5,235,467	New	+$234M	0.04%	532

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fidelity Investments's JUNO Position: Q1 2018 in Review

Fidelity Investments sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 2,736,527 shares — an estimated $125M sold.

Fidelity Investments first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $390M in Q1 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Fidelity Investments reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Fidelity Investments sold 2,736,527 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $125M.
Fidelity Investments first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
Fidelity Investments's Juno Therapeutics, Inc. position peaked at $390M in Q1 2015.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Fidelity Investments's 13F filing for Q1 2018, filed 14 May 2018.